Loading
Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.
Latest quote
¥369
−¥27.00 · -6.82%
Regular session · JST · Market data may be delayed.
Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.
Day range
Current ¥369
52-week range
Current ¥369
Regular session · JST · Market data may be delayed.
Veritas In Silico Inc. engages in the development of molecular medicine drugs. It provides a platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. The company was founded by Shingo Nakamura on November 17, 2016 and is headquartered in Tokyo, Japan.
Day range
Current ¥369
52-week range
Current ¥369
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
